Halozyme and Skye partner on obesity drug delivery technology
Go back to Halozyme and Skye partner on obesity drug delivery technology| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 103.90 +5.24 (5.31%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $98.66 | 52 Week High | $18.39 | |||
| Open | $98.86 | 52 Week Low | $6.96 | |||
| Day High | $104.09 | P/E | N/A | |||
| Day Low | $98.58 | EPS | $-0.58 | |||
| Volume | 1,138,949 | |||||
| (NASDAQ: SKYE) | Delayed: 0.45 -0.05 (10%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.50 | 52 Week High | $ | |||
| Open | $0.57 | 52 Week Low | $ | |||
| Day High | $0.59 | P/E | N/A | |||
| Day Low | $0.45 | EPS | $ | |||
| Volume | 8,440,676 | |||||
